Advertisement

Topics

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 63-page report is available in PDF from $2000.

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Dementia Associated With Alzheimer's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dementia Associated With Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dementia Associated with Alzheimer's disease Overview 6
Therapeutics Development 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 8
Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 9
Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 10
Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Dementia Associated With Alzheimer's Disease - Products under Development by Companies 14
Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 15
Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 16
Actinogen Limited 16
Chase Pharmaceuticals Corporation 17
Eisai Co., Ltd. 18
FORUM Pharmaceuticals Inc. 19
MediPost Co., Ltd. 20
Neurodyn Inc. 21
Otsuka Holdings Co., Ltd. 22
Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
aripiprazole - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVCRI-104P3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
brexpiprazole - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CPC-201 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-2609 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
encenicline hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gln-1062 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Neurostem - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Product Description 47
Mechanism of Action 47
R&D Progress 47
UE-2343 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates 49
Dementia Associated With Alzheimer's Disease - Dormant Projects 59
Dementia Associated With Alzheimer's Disease - Discontinued Products 60
Dementia Associated With Alzheimer's Disease - Product Development Milestones 61
Featured News & Press Releases 61
Apr 13, 2015: EU Patent Granted - Further Extends Xanamem Protection 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
For more information open Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015.

SKU: GMDHC6632IDB

Original Article: Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...